Genmab A/S is to receive $2 million upfront from Novartis as part of a new collaboration in which the Swiss multinational will use Genmab technology to identify candidate bispecific antibodies against two disease target combinations. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals